Similar articles

• [Aquaretic agents].

  Bosch-Marcé M, Clària J, Jiménez W. Bosch-Marcé M, et al. Gastroenterol Hepatol. 1996 Nov;19(9):472-7. Gastroenterol Hepatol. 1996. PMID: 8998673 Review. Spanish. No abstract available.
• Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.

  Bosch-Marcé M, Poo JL, Jiménez W, Bordas N, Leivas A, Morales-Ruiz M, Muñoz RM, Pérez M, Arroyo V, Rivera F, Rodés J. Bosch-Marcé M, et al. J Pharmacol Exp Ther. 1999 Apr;289(1):194-201. J Pharmacol Exp Ther. 1999. PMID: 10087004
• Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention.

  Bosch-Marcé M, Jiménez W, Angeli P, Leivas A, Clària J, Graziotto A, Arroyo V, Rivera F, Rodés J. Bosch-Marcé M, et al. Gastroenterology. 1995 Jul;109(1):217-23. doi: 10.1016/0016-5085(95)90287-2. Gastroenterology. 1995. PMID: 7797019
• Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.

  Ferguson JW, Therapondos G, Newby DE, Hayes PC. Ferguson JW, et al. Clin Sci (Lond). 2003 Jul;105(1):1-8. doi: 10.1042/CS20030062. Clin Sci (Lond). 2003. PMID: 12639215 Review.
• Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.

  Jiménez W, Gal CS, Ros J, Cano C, Cejudo P, Morales-Ruiz M, Arroyo V, Pascal M, Rivera F, Maffrand JP, Rodés J. Jiménez W, et al. J Pharmacol Exp Ther. 2000 Oct;295(1):83-90. J Pharmacol Exp Ther. 2000. PMID: 10991964